Blue Horseshoe Stocks: Options Review & More

Options Review

Bed Bath & Beyond, Inc. BBBY – Yesterday morning’s premarket report contained an options idea for Bed Bath & Beyond following the company’s quarterly earnings report, the BBBY Weekly $13 & $13.50 Calls, and those plays both turned in fantastic intraday performances.

Regardless of which strike point was chosen, traders could have secured multi-bag profits on the day. The $13 Calls traded up from a low of .30 to a high of 1.30, for an increase of 333%, while the $13.50′s also crushed it with a huge 431% rip from .16-.85!
_______

Constellation Brands Inc. STZ -Just as Constellation stock got crushed to new lows in the premarket on Wednesday, we formulated a couple of longer-term options ideas, and wanted to provide updates on the activity there as well.

We were banking on STZ reversing off of those lows and beginning a recovery, and so far, it’s going quite well. Our targets were the  the STZ 02/01 $150-157.50 Calls and the 04/18 $160-170 Calls, and all seven sets of contracts in those ranges have been good for significant gain opportunities. These remain in play, and will remain on our watchlist going forward.

02/01 $150-157.50 Calls
$150 Calls – Range: 8.80-11.50 – Max Gain: 31%
$152.50 Calls – Range: 3.80-6.70 – Max Gain: 76%
$155 Calls – Range: 2.90-8.00 – Max Gain: 176%
$157.50 Calls – Range: 3.00-6.65 – Max Gain: 122%

04/18 $160-170 Calls

$160 Calls – Range: 5.50-10.83 – Max Gain: 97%
$165 Calls – Range: 4.00-8.01 – Max Gain: 101%
$170 Calls – Range: 2.78-6.07 – Max Gain: 118%
_____

Fresh Ideas:
GM Weekly $36-37.50 Calls
TLRY Weekly $92.50-95 Calls  


China SXT Pharma Inc SXTC

To wrap things up we wanted to go over the call we made on Monday morning in SXTC, which at the time had registered a low of 5.684. After steadily ramping up all week, yesterday the stock reached a new high of 23.35. That worked out to an incredible four-day swing of 311%

Cheers to anyone who caught this mover in Monday morning’s premarket report. It adds to an already impressive start for us here in 2019.


Extended Watchlist:
FTK, AQMS, MGEN, NAVB, SNSS, CFRX, TEUM

Blue Horseshoe Stocks: INFI Review & More

Infinity Pharmaceuticals, Inc. INFI

The stock with the most notable performance from yesterday morning’s watchlist was definitely INFI, which began trending up in the premarket, and continued its climb throughout the entire session.

The stock traded up from a low of 2.44 to 3.75, which works out to an intraday rise of 54% and it came on roughly 38X its monthly average volume. An early pullback from profit taking this morning would be a likely scenario, but if INFI can find support at a higher point than yesterday’s low, from



AcelRx Pharmaceuticals, Inc. ACRX

After the FDA’s rejecion of the company’s ‘Dsuvia” opioid painkiller, ACRX took a monstrous pounding yesterday down to its lowest price in three months.

As you can see on the chart, it fell all the way down to an area of support it had established back in July. We’ll be interested to monitor this play for a bottom, which could come at any time. Moves generated by FDA news, whether positive or negative, tend to be over-exaggerated and are almost always followed by a course correction.


Inotek Pharmaceuticals Corp ITEK

Here we have an example of being extremely ‘early to the party’ as we sometimes say. We alerted on ITEK back in July, after which point it saw a low of .89. It mostly traded sideways throughout the remainder of the summer, but recently began quite an impressive climb.

This morning, the stock hit news highs of 4.15 in premarket trading on news of a proposed merger with a clinical stage gene therapy company. It may have took a few months to realize, but it works out to an increase of 366%

For an added angle going forward, we’ll also signal the ITEK 10/20 $2.50 Calls for possible daytrades and/or swing trades into next week, and the 11/17 $2.50 & $5.00 Calls for a longer term idea.


Extended Watchlist:
SONS, MARK, HSC, DPW, AKS, CLF, RIG, ATNM, MGEN